13754-45-5

Basic information

• Product Name: 1-(2-CHLORO-BENZOYL)-PIPERAZINE
• Synonyms: AKOS BB-6375;1-(2-CHLORO-BENZOYL)-PIPERAZINE;(2-CHLORO-PHENYL)-PIPERAZIN-1-YL-METHANONE;BUTTPARK 145\16-04;1-(2-CHLORO-BENZOYL)-PIPERAZINE >98%
• CAS NO: 13754-45-5
• Molecular Formula: C₁₁H₁₃ClN₂O
• Molecular Weight: 224.69
• Product Categories: Piperaizine;piperazines
• Mol File: 13754-45-5.mol

Chemical Properties

• Melting Point: 195 °C
• Boiling Point: 383.8 °C at 760 mmHg
• Flash Point: 185.9 °C
• Appearance: /
• Density: 1.231 g/cm³
• Vapor Pressure: 4.3E-06mmHg at 25°C
• Refractive Index: 1.57
• Storage Temp.: 2-8°C
• PKA: 8.44±0.10(Predicted)
• CAS DataBase Reference: 1-(2-CHLORO-BENZOYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-CHLORO-BENZOYL)-PIPERAZINE(13754-45-5)
• EPA Substance Registry System: 1-(2-CHLORO-BENZOYL)-PIPERAZINE(13754-45-5)

Safety Data

• Hazard Codes: Xn
• Statements: 22-36
• Safety Statements: 26
• Hazardous Substances Data: 13754-45-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-CHLORO-BENZOYL)-PIPERAZINE is used as a chemical intermediate for the synthesis of various drugs, including antipsychotics, antidepressants, and antihistamines. Its unique structure allows for the development of medications that can target specific receptors in the body, providing therapeutic benefits for a range of conditions.
Used in Anticancer Research:
1-(2-CHLORO-BENZOYL)-PIPERAZINE is studied for its potential anti-cancer properties. Its ability to interact with cellular pathways and inhibit the growth of cancer cells makes it a promising candidate for further research and development in oncology.
Used in Anti-inflammatory Applications:
1-(2-CHLORO-BENZOYL)-PIPERAZINE has also been investigated for its potential anti-inflammatory effects. Its capacity to modulate inflammatory responses could lead to the development of treatments for conditions characterized by chronic inflammation.
Used in Psychiatric Disorders Treatment:
Due to its sedative and anti-anxiety effects, 1-(2-CHLORO-BENZOYL)-PIPERAZINE holds potential as a therapeutic agent for the treatment of psychiatric disorders. Its calming properties may contribute to the management of anxiety and other related conditions, although further research is necessary to confirm its efficacy and safety in this context.

InChI:InChI=1/C11H13ClN2O/c12-10-4-2-1-3-9(10)11(15)14-7-5-13-6-8-14/h1-4,13H,5-8H2

Upstream product

• 110-85-0 piperazine 
• 609-65-4 o-chlorobenzoyl chloride 
• 142-64-3 piperazine dihydrochloride 
• 118-91-2 ortho-chlorobenzoic acid 

Downstream Products

• 892495-26-0 2-[4-(2-chlorobenzoyl)-1-piperazinomethyl]-3,5,6-trimethylpyrazine 
• 1226894-87-6 C₂₇H₃₁ClF₃N₅O₃ 
• 1228934-35-7 1-{4-[3-{4-(2-chlorobenzoyl)piperazin-1-yl}propoxy]phenyl}ethanone 
• 1228934-37-9 1-{2-[3-{4-(2-chlorobenzoyl)piperazin-1-yl}propoxy]phenyl}ethanone 
• 1373134-07-6 1-(3-[3-{4-(2-chlorobenzoyl)piperazin-1-yl}propoxy]phenyl)ethanone 
• 1373134-05-4 3-[3-{4-(2-chlorobenzoyl)piperazin-1-yl}propoxy]benzaldehyde 
• 1075248-09-7 C₂₁H₁₇ClN₂O₄ 
• 1075248-23-5 C₂₁H₁₉ClN₂O₃ 

Relevant articles and documents

Looking toward the Rim of the Active Site Cavity of Druggable Human Carbonic Anhydrase Isoforms

We report the synthesis and biochemical evaluation of a series of substituted 4-(4-aroylpiperazine-1-carbonyl)benzenesulfonamides (5a-s) developed as inhibitors of druggable carbonic anhydrase (CA) isoforms, as tools for the identification of new therapeu

Synthesis, characterization, and anti-inflammatory activities of methyl salicylate derivatives bearing piperazine moiety

In this study, a new series of 16 methyl salicylate derivatives bearing a piperazine moiety were synthesized and characterized. The in vivo anti-inflammatory activities of target compounds were investigated against xylol-induced ear edema and carrageenan-induced paw edema in mice. The results showed that all synthesized compounds exhibited potent anti-inflammatory activities. Especially, the anti-inflammatory activities of compounds M15 and M16 were higher than that of aspirin and even equal to that of indomethacin at the same dose. In addition, the in vitro cytotoxicity activities and anti-inflammatory activities of four target compounds were performed in RAW264.7 macrophages, and compound M16 was found to significantly inhibit the release of lipopolysaccharide (LPS)-induced interleukin (IL)-6 and tumor necrosis factor (TNF)-α in a dose-dependent manner. In addition, compound M16 was found to attenuate LPS induced cyclooxygenase (COX)-2 up-regulation. The current preliminary study may provide information for the development of new and safe anti-inflammatory agents.

Expanding the structural diversity of Bcr-Abl inhibitors: Hybrid molecules based on GNF-2 and Imatinib

In order to expand the structural diversity of Bcr-Abl inhibitors, twenty hybrids (series E and P) have been synthesized and characterized based on Imatinib and GNF-2. Their biological activities were evaluated in vitro against human leukemia cells. Most compounds exhibited potent antiproliferative activity against K562 cells, especially for compounds E4, E5 and E7. Furthermore, these new hybrids were also screened for Abl kinase inhibitory activity, and some of them inhibited Abl kinase with low micromolar IC50 values. In particular, compound P3 displayed the most potent activity with IC50 value of 0.017 μM comparable with that of Imatinib. Molecular docking studies indicated that these novel hybrids fitted well with the active site of Bcr-Abl. These results suggested the great potential of these compounds as novel Bcr-Abl inhibitors.

Discovery of novel Bcr-Abl inhibitors targeting myristoyl pocket and ATP site

Bcr-Abl plays an essential role in the pathogenesis and development of chronic myeloid leukaemia (CML). Inhibition of Bcr-Abl has great potential for therapeutic intervention in CML. In order to obtain novel and potent Bcr-Abl inhibitors, twenty seven 4,6-disubstituted pyrimidines were synthesized and evaluated herein. The biological results indicated that four compounds of them (C4, C5, C16, and C23) were potent Bcr-Abl inhibitors which were comparable to positive control. Moreover, C4 and C5 displayed promising antiproliferative activity against K562 cells. The results suggested that these 4,6-disubstituted pyrimidines could serve as promising leads for further optimization of Bcr-Abl inhibitors.

Synthesis and evaluation of meta substituted 1-(aryloxypropyl)-4- (chloroaryl) piperazines as potential atypical antipsychotics

A series of 1-(aryloxypropyl)-4-(chloroaryl) piperazines have been synthesized based upon their physicochemical similarity with respect to standard atypical antipsychotic drugs and their potential to cross the blood-brain barrier (log BB) as calculated by

Synthesis, evaluation and computational studies on a series of acetophenone based 1-(aryloxypropyl)-4-(chloroaryl) piperazines as potential atypical antipsychotics

A series of 1-(aryloxypropyl)-4-(chloroaryl) piperazines have been synthesized and the target compounds evaluated for atypical antipsychotic activity in apomorphine induced mesh climbing and stereotypy assays in mice. The compounds 11 and 12 have emerged